Mike Nohaile is senior vice president of strategy, commercialization, and innovation at biotechnology firm Amgen. He joined Amgen as vice president of strategy in 2012. Prior to Amgen, Nohalie served as head and general manager of the Molecular Diagnostics Business Unit at Novartis, where he previously served as the head of corporate strategy and head of pharmaceutical strategy. Nohaile began his career at McKinsey & Company, where as a partner in the New Jersey office he worked extensively in the health care area with a particular focus on diagnostics, devices, and pharmaceuticals. After earning his doctorate in molecular and cell biology, he was a postdoctoral fellow at MIT Biology Department.
Previously
Artificial intelligence is an increasingly valuable coin of the realm in medicine. It is already playing a role in disease diagnosis, drug development, surgery, maternal and c...